Karuna Therapeutics (KRTX) Earnings
Price: $329.83
Market Cap: $12.60B
Market Cap: $12.60B
Revenue (TTM): $654.00K
Net Income: $-433.68M
Net Income: $-433.68M
P/E Ratio: -37.08
EPS (TTM): $-8.90
EPS (TTM): $-8.90
Earnings Dates
Karuna Therapeutics (KRTX) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date:
- Time of Day:
- Estimated EPS: $N/A
Last Earnings Report
- Date: May 02, 2024
- EPS: $-2.80
- EPS Estimate: $-3.06
Karuna Therapeutics's next earnings report is scheduled for .
In its last earnings report on May 02, 2024, Karuna Therapeutics reported earnings per share (EPS) of $-2.80, compared to an estimated EPS of $-3.06. The company reported revenue of $-, compared to an estimated revenue of $340.00K.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2023 | 2023-11-05 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-05 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| May 02, 2024 | $-2.80 | $-3.06 | $- | $340.00K |
| February 22, 2024 | $-3.01 | $-2.64 | $- | $760.00K |
| November 02, 2023 | $-3.16 | $-2.74 | $- | $1.25M |
| August 03, 2023 | $-2.75 | $-2.76 | $- | $360.00K |
| May 04, 2023 | $-2.80 | $-2.86 | $654.00K | $- |
| February 23, 2023 | $-2.22 | $-2.23 | $5.28M | $7.14K |
| November 03, 2022 | $-2.38 | $-1.99 | $81.00K | $916.67K |
| August 08, 2022 | $-2.17 | $-2.02 | $5.28M | $- |
| May 05, 2022 | $-1.95 | $-2.06 | $- | $- |
| February 24, 2022 | $-0.94 | $-1.52 | $36.96M | $7.78M |
| November 04, 2021 | $-1.72 | $-1.40 | $- | $- |
| August 05, 2021 | $-1.17 | $-1.24 | $- | $- |
| May 06, 2021 | $-1.10 | $-1.06 | $- | $- |
| February 25, 2021 | $-0.89 | $-0.91 | $- | $- |
| November 05, 2020 | $-0.71 | $-0.76 | $- | $- |
| August 05, 2020 | $-0.65 | $-0.44 | $- | $- |
| May 07, 2020 | $-0.33 | $-0.45 | $- | $- |
| March 24, 2020 | $-0.32 | $-0.47 | $- | $- |
| November 07, 2019 | $-0.39 | $-0.51 | $- | $- |
| August 08, 2019 | $-0.65 | $-0.87 | $- | $- |
Annual Earnings
Annual Revenue
$654.00K
Fiscal Year 2023Annual Net Income
$-433.68M
Fiscal Year 2023Annual EPS
$-11.73
Fiscal Year 2023Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2023Net Income
$-113.82M
Quarter Ending December 31, 2023EPS
$-3.01
Quarter Ending December 31, 2023Earnings Metrics
Earnings Yield
-3.71%
Year Ending December 31, 2023P/E Ratio
-26.97
Year Ending December 31, 2023Revenue Per Share
$0.02
Year Ending December 31, 2023Earnings Yield (TTM)
-2.70%
Trailing Twelve MonthsP/E Ratio (TTM)
-37.08
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.00
Trailing Twelve MonthsFrequently Asked Questions
Karuna Therapeutics's next earnings date is scheduled for . The earnings call is expected to take place .
In its last earnings report on May 02, 2024, Karuna Therapeutics reported earnings per share (EPS) of $-2.80, compared to an estimated EPS of $-3.06. The company reported revenue of $-, compared to an estimated revenue of $340.00K.
Karuna Therapeutics's current Price-to-Earnings (P/E) ratio is -26.97. The trailing twelve months (TTM) P/E ratio is -37.08. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2023, Karuna Therapeutics reported total revenue of $654.00K and net income of $-433.68M. This represents a net profit margin of -663.119266055.
Karuna Therapeutics's earnings yield is -3.71%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Karuna Therapeutics's return on equity (ROE) is -34.58%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Karuna Therapeutics's gross profit margin is -160.10%. This indicates that for every dollar of revenue, the company retains $-1.60 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for KRTX.